PDCD1 and neoplasm: In patients with NSCLC and treated with pembrolizumab, some tumoural non-synonymous mutations above the cohort’s median have been associated with higher ORR and longest PFS.145,148 Interestingly, these studies have also suggested that patients with PD-L1+ tumours and high mutational burdens exhibit the highest sensitivity to anti-PD-1 therapy (ORR 91%).